Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Jun 27, 2025; 17(6): 101206
Published online Jun 27, 2025. doi: 10.4240/wjgs.v17.i6.101206
Published online Jun 27, 2025. doi: 10.4240/wjgs.v17.i6.101206
Understanding the risk factors of hemagglutinase-associated hypofibrinogenemia can improve the prognosis of patients
Ying-Fang Deng, Xian-Shu Cui, Department of Oncology, Affiliated Hospital of Qinghai University, Xining 810000, Qinghai Province, China
Ya-Qi Zhao, Graduate School of Qinghai University, Affiliated Hospital of Qinghai University, Xining 810000, Qinghai Province, China
Liang Wang, Department of Gastrointestinal Oncology Surgery, Affiliated Hospital of Qinghai University, Xining 810000, Qinghai Province, China
Co-first authors: Ying-Fang Deng and Ya-Qi Zhao.
Co-corresponding authors: Liang Wang and Xian-Shu Cui.
Author contributions: Deng YF and Zhao YQ co-wrote the manuscript, sharing the first authorship; Deng YF and Wang L reviewed the literature; Wang L revised and reviewed the manuscript; Cui XS contributed to the editorial concept and design; all authors have read and approved the final manuscript.
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xian-Shu Cui, Department of Oncology, Affiliated Hospital of Qinghai University, No. 29 Tongren Road, Xining 810000, Qinghai Province, China.
Received: September 7, 2024
Revised: March 4, 2025
Accepted: March 17, 2025
Published online: June 27, 2025
Processing time: 265 Days and 5.8 Hours
Revised: March 4, 2025
Accepted: March 17, 2025
Published online: June 27, 2025
Processing time: 265 Days and 5.8 Hours
Core Tip
Core Tip: Potential hazards underlying hypofibrinogenemia resulted from hemocoagulase include age, gender, lower baseline fibrinogen levels, route of administration, type of hemocoagulase, cumulative dose, treatment duration, and albumin levels. It's of great significance to understand the above risk factors of hemagglutinase-associated hypofibrinogenemia for improving the prognosis of patients.